Advertisement

Topics

Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada

05:00 EDT 3 Jul 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Promethera Biosciences SA, a global innovator in cell-based medicines, today announced that Health Canada has accepted its New Drug Submission (NDS) of Heparesc in neonatal onset Urea Cycle Disorders (UCD) for review. UCDs are u...

Other Sources for this Article

Promethera Biosciences SA
Alexandra Schiettekatte
Alexandra.schiettekatte@promethera.com
Web: www.promethera.com
or
For media:
MacDougall Communications
Gretchen Schweitzer
or Mario Brkulj
+49 89 2424 3494
or +49 175 501 0575
mbrkulj@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...